Skip to main content
. Author manuscript; available in PMC: 2022 Oct 29.
Published in final edited form as: J Med Chem. 2021 Oct 12;64(20):15313–15333. doi: 10.1021/acs.jmedchem.1c01353

Figure 3.

Figure 3.

The eticlopride analogues 13, 15, 17b, 48, 49 were all antagonists or very weak partial agonists at both D3R and D2R. The Go BRET activation assays show that these compounds have very low efficacies at both D3R (A) and D2R (B) similar to levels of the reference antagonist eticlopride, compared to the full agonist quinpirole.